CJC-1295
Also known as: cjc1295, cjc 1295, drug affinity complex growth hormone releasing factor, dac:grf, cjc-1295 dac
Long-acting GHRH analogue that stimulates growth hormone secretion; often combined with Ipamorelin.
Quick Reference
CJC-1295 - Research Images
PSO vial render · Scientific images from Wikipedia · Tap to enlarge
Overview
Chemical compound
CJC-1295 DAC, also known as DAC:GRF, is a synthetic analogue of growth hormone-releasing hormone (GHRH) and a growth hormone secretagogue (GHS) which was developed by ConjuChem Biotechnologies. It is a modified form of GHRH (1-29) with improved pharmacokinetics, especially in regard to half-life.
Mechanism of Action
Mimics endogenous GHRH, binds GHRH receptors; DAC modification extends half-life by albumin binding.
What is CJC-1295?
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) studied for its unusually long action. By attaching a chemical anchor called a Drug Affinity Complex, researchers extended its activity from minutes to days, so a single exposure keeps stimulating growth hormone pulses far longer than natural GHRH. Published trials tested it in healthy adults. It is not FDA approved.
How It Works - Simply Explained
Natural GHRH vanishes from the bloodstream in minutes. CJC-1295's Drug Affinity Complex binds to albumin in the blood, creating a slow-release reservoir. In studies, this meant one dose kept nudging the pituitary to release growth hormone in natural pulses for days. Researchers found this preserved the body's normal pulsatile rhythm instead of flooding the system, which is the elegant part of the design.
What Studies Have Found
Days of elevated GH and IGF-1 from a single dose
In a published trial in healthy adults, researchers found that CJC-1295 raised growth hormone and IGF-1 levels for several days after administration. The effect was dose-dependent: higher tested doses produced larger and longer-lasting elevations. For a hormone signal that normally lasts minutes, multi-day activity was the headline result.
Teichman et al., 2006, Journal of Clinical Endocrinology and Metabolism
Natural pulses preserved during continuous stimulation
A companion study asked a deeper question: does constant stimulation flatten the body's natural growth hormone rhythm? The researchers found that pulsatile secretion persisted even during continuous CJC-1295 exposure. That matters because the pulse pattern, not just the total amount, is how the system is designed to work.
Ionescu and Frohman, 2006, Journal of Clinical Endocrinology and Metabolism
Dose-dependent responses in human testing
Across the tested dose range, researchers observed orderly dose-response relationships for both growth hormone and IGF-1. The trials reported the compound was generally well tolerated at the studied doses, with the expected profile of a GHRH-pathway agent. These human data are why CJC-1295 remains one of the most referenced long-acting GHRH analogs in the literature.
Teichman et al., 2006, Journal of Clinical Endocrinology and Metabolism
The DAC anchor: what makes it different from short-acting versions
The Drug Affinity Complex is a chemical modification that latches onto blood albumin, shielding the peptide from rapid breakdown. Researchers showed this single design change stretched the active window from minutes to days. The non-DAC version, often called Modified GRF 1-29, lacks this anchor and behaves like a short-acting GHRH signal instead.
CJC-1295 development literature, 2000s, peptide therapeutic reviews
Last updated 2026-10-06. New findings are added as published research appears.
Frequently Asked Questions
What is CJC-1295?
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) modified with a Drug Affinity Complex that extends its activity to days. It was studied in human trials for its ability to stimulate pulsatile growth hormone release. It is for laboratory research only and is not FDA approved.
What does DAC mean?
DAC stands for Drug Affinity Complex. It is a chemical anchor attached to the peptide that binds to albumin in the blood. This protects the peptide from rapid breakdown and creates a slow-release effect, which is why CJC-1295 with DAC acts for days instead of minutes.
How is CJC-1295 different from Modified GRF 1-29 or sermorelin?
Modified GRF 1-29 (often sold without DAC) and sermorelin are short-acting GHRH signals that clear in minutes. CJC-1295 with DAC carries the albumin-binding anchor, so published studies show it stimulating growth hormone pulses for days from a single exposure.
Is CJC-1295 FDA approved?
No. CJC-1295 is an investigational research compound. It has not been approved by the FDA for any indication, and products sold online are for in-vitro laboratory research only, not for human consumption.
What did human trials find?
Published trials in healthy adults found dose-dependent increases in growth hormone and IGF-1 lasting several days, with pulsatile secretion patterns preserved. Researchers described it as generally well tolerated at the studied doses.
Why do researchers study it with ipamorelin?
The two work through different receptors that converge on the same pituitary cells. Published research showed the combination produced larger growth hormone pulses than either compound alone, making the pair a standard object of study.
Can I use CJC-1295 personally?
No. CJC-1295 from research suppliers is for laboratory research only. It is not for human consumption, has not been evaluated by the FDA, and is not a medicine. This page describes published research only.
What Researchers Are Saying
Community Reports - Not Medical Advice
The following is aggregated from public forums, Reddit, and research communities. These are anecdotal reports from researchers only - not verified clinical data and not a recommendation of any kind.
CJC-1295 (also known as cjc1295, cjc 1295) is studied within the growth hormone axis and body composition research community. Long-acting GHRH analogue that stimulates growth hormone secretion; often combined with Ipamorelin.
Last updated October 28, 2026
Research status: active. CJC-1295 appears across growth hormone axis and body composition research forums and academic literature. Researchers note this compound falls in the growth hormone category.
Last updated October 28, 2026
What Do You Think of This Peptide?
Share your opinion or research experience with CJC-1295. Comments are reviewed before appearing.